Nuveen Asset Management, LLC Arcus Biosciences, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 169,853 shares of RCUS stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

169,853

Previous 167,301 1.53%

Holding current value

$2.5 Million

Previous $2.55 Million 1.96%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $34,936 - $45,961	2,552 Added 1.53%	169,853 $2.6 Million
Q2 2024 Aug 09, 2024	BUY	$14.59 - $18.48 $584,796 - $740,715	40,082 Added 31.51%	167,301 $2.55 Million
Q1 2024 May 13, 2024	SELL	$14.83 - $20.18 $92,361 - $125,681	-6,228 Reduced 4.67%	127,219 $2.4 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $4.44 Million - $6.49 Million	-330,476 Reduced 71.24%	133,447 $2.55 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $101,843 - $136,061	5,780 Added 1.26%	463,923 $8.33 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $286,826 - $372,351	16,902 Added 3.83%	458,143 $9.3 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $4.77 Million - $6.92 Million	298,925 Added 210.04%	441,241 $8.05 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $479,872 - $869,859	-24,359 Reduced 14.61%	142,316 $2.94 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $115,127 - $149,026	-4,956 Reduced 2.89%	166,675 $4.36 Million
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $1.49 Million - $3.26 Million	-86,371 Reduced 33.48%	171,631 $4.35 Million
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $35,398 - $51,199	-1,224 Reduced 0.47%	258,002 $8.93 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $590,477 - $912,059	-18,817 Reduced 6.77%	259,226 $10.1 Million
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $3.96 Million - $5.54 Million	-147,031 Reduced 34.59%	278,043 $10.1 Million
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $5.76 Million - $9.05 Million	253,089 Added 147.16%	425,074 $11.7 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $858,152 - $1.36 Million	-32,804 Reduced 16.02%	171,985 $4.83 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $196,571 - $374,178	-11,563 Reduced 5.34%	204,789 $5.32 Million
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $1.12 Million - $1.66 Million	-65,075 Reduced 23.12%	216,352 $3.71 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $632,938 - $1.66 Million	45,307 Added 19.19%	281,427 $6.96 Million
Q1 2020 May 14, 2020	BUY	$8.78 - $19.28 $438,631 - $963,190	49,958 Added 26.84%	236,120 $3.28 Million
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $335,032 - $493,178	45,707 Added 32.54%	186,162 $1.88 Million
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $44,835 - $70,873	6,962 Added 5.22%	140,455 $1.28 Million
Q2 2019 Aug 15, 2019	BUY	$7.29 - $13.38 $973,163 - $1.79 Million	133,493 New	133,493 $1.06 Million

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Arcus Biosciences, Inc. Transaction History